Novo Nordisk Insulin Revenue Drives 1Q Profits

Novo Nordisk Insulin Revenue Drives 1Q Profits Play

May 1 (Bloomberg) -- Bloomberg Europe business correspondent Caroline Hyde reports that Novo Nordisk A/S announced a 28 percent increase in first-quarter profit as sales climbed for its insulins and the Victoza diabetes treatment. She speaks on Bloomberg Television's "The Pulse."

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus